



Further · Closer · Together

3RD QUARTER AND FIRST NINE MONTHS FINANCIAL REPORT 2012*

REGULATED INFORMATION

OCTOBER 25 2012, 7.30 AM BRUSSELS TIME



SOLVAY GROUP

3RD QUARTER 2012 BUSINESS REVIEW*

Highlights

Continued earnings strength supported by the growth engines and highly resilient businesses, and strong cash flow generation

- Net sales up 1% to EUR 3,291 million yoy with volumes (4)%, stable prices and forex +5%
- REBITDA at EUR 554 million +4% yoy
 - Record results in Consumer Chemicals (good demand and continued exceptional earnings contribution from its Indian native-guar JV) and in Specialty Polymers
 - Resilient growth performance in Essential Chemicals and Acetow & Eco Services while Advanced Materials' Rare Earths slowed down
 - Persisting difficult market conditions for Polyamide Materials and Vinyls
 - Confirmed pricing power Group-wise: In an inflationary context, selling price increases compensated rise in raw material and energy costs yoy, despite challenging business conditions at our cycle-sensitive businesses
- Adj EBIT¹ at EUR 329 million compared to pro forma EUR 355 million last year, reflecting higher non-recurring items linked to the integration and cost efficiencies programs
- Adjusted Net Income¹ (Group Share) of EUR 148 million
- Free Cash Flow of EUR 346 million and improved Net Debt to EUR 1.5 billion versus EUR 1.8 billion in Q2'12
- Interim dividend of EUR 0.90 net per share (EUR 1.20 gross per share)

1. IFRS measures: EBIT 3rd quarter 2012 at 298 million versus EUR 148 million in the last year quarter; Net Income (Group share) 3rd quarter 2012 at 125 million versus EUR 73 million in the last year quarter

Quote of the CEO

While differentiated market dynamics by business segments persisted in the 3rd quarter, the breadth and quality of the product portfolio allowed Solvay to post another set of good results. The earnings strength combined with an effective working capital management generated a strong free cash flow. With the capacity extensions for its growth engines, Solvay continues executing its strategic journey towards its growth ambition. The integration progresses very well, establishing a solid foundation for the Group to move forward.

Outlook

The fragile macroeconomic environment reduces visibility across markets and industries. The 4th quarter will reflect seasonal inventory management from customers and the slowdown of some market segments. The good momentum of the integration and the re-design of the Group's organisation strengthen our confidence in the delivery of synergies and savings as planned. In this framework, Solvay confirms its expectation to achieve a full year REBITDA similar to the strong 2011 pro forma level.

* Footnote applicable to the entire document: All references to year-on-year (yoy) evolution must be understood on a pro forma basis for 2011, as if the acquisition of Rhodia had become effective from the 1st of January 2011. On a pro forma basis Solvay 2011 historical figures were restated in order to have harmonized accounting policies among the two former Groups, policies that are to be used by the new Solvay going forward. Pro forma results exclude impacts from i) purchase price allocation entries; ii) non-recurring acquisition costs related to the Rhodia transaction and iii) financial revenues on cash deposits and investments. Adjusted Profit & Loss indicators exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.

All period changes throughout this document are to be deemed on a year-on-year bases unless otherwise stated.

REBITDA: Operating result before depreciation and amortization, non-recurring items, financial charges and income taxes

SOLVAY GROUP

3RD QUARTER 2012 BUSINESS REVIEW*

Key data (in million EUR)	Adjusted ¹ Q3 2012	Pro Forma ² Q3 2011	YoY evolution (%)	Adjusted ¹ 9M 2012	Pro Forma ² 9M 2011	YoY evolution (%)
Net Sales ³	3,291	3,256	1%	9,861	9,696	2%
REBITDA ⁴	554	533	4%	1,642	1,711	(4)%
REBIT	383	366	5%	1,127	1,225	(8)%
Non-recurring items	(54)	(11)	n.a.	(48)	14	n.a.
EBIT	329	355	(7)%	1,079	1,239	(13)%
Net financial expenses	(98)	(99)	1%	(287)	(264)	(9)%
Result before taxes	231	256	(10)%	790	976	(19)%
Income taxes	(66)	(103)	36%	(245)	(272)	10%
Net result from continuing operations	165	153	8%	545	704	(23)%
Net result from discontinued operations ⁵	(2)	6	n.a.	1	(38)	n.a.
Net income	163	160	2%	546	667	(18)%
Non controlling interests	(15)	(17)	10%	(38)	(54)	33%
Net income, Group share	148	143	3%	508	613	(17)%
Free cash flow ⁶	346	223	55%	536	391	37%

- Adjusted performance indicators exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.
- Pro forma figures shown in the income statement (a) as if the acquisition had become effective from 1st of January 2011, (b) harmonizing accounting principles and (c) excluding the Purchase Price Allocation (PPA) impacts.
- Net sales comprise the sales of goods and value added services corresponding to Solvay's know-how and core business. Net sales exclude other revenues primarily comprising commodity and utility trading transactions and other revenue deemed as incidental by the Group.
- REBITDA: operating results before depreciation and amortization, non-recurring items, financial charges and income taxes.
- The net results from discontinued operations is linked to post-closing adjustments subsequent to the sale of the pharmaceutical activities.
- Cash flow from operating activities (including dividends from associates and joint ventures) + cash flow from investing activities (excluding acquisitions and sales of subsidiaries and other investments).

Net sales

EUR **3,291** million
+1%

REBITDA

EUR **554** million
+4%

Adj. net income

EUR **148** million
Adj. EPS (basic)
EUR **1.79**

YoY evolution (%) compared with pro forma 3RD quarter 2011

SOLVAY GROUP

3RD QUARTER AND YEAR-TO-DATE (9 MONTHS) 2012*

Key data (in million EUR)	Adjusted Q3 2012	YoY evolution (%)	Adjusted 9M 2012	YoY evolution (%)
Net sales	3,291	1%	9,861	2%
Plastics	994	8%	2,943	3%
Chemicals	758	7%	2,253	5%
Rhodia	1,540	(6)%	4,665	(1)%
REBITDA	554	4%	1,642	(4)%
Plastics	168	8%	450	(14)%
Chemicals	145	21%	439	13%
Rhodia	290	4%	869	(2)%
New Business Development	(17)	(68)%	(38)	(27)%
Corporate and Business Support	(32)	(170)%	(78)	(41)%
EBIT	329	(7)%	1,079	(13)%

Business review – 9 months 2012

Net sales reached EUR 9,861 million, up by 2% versus the first nine months of 2011. This improvement is reflected in the Plastics and Chemicals sectors; net sales decreased in the Rhodia sector. The (4)% lower volumes were more than compensated by average selling price increases of +2%, favorable currency impact of +4% and scope changes of +1%. The volume decline is mainly linked to the high demand dynamics observed last year and to the economic slowdown that severely impacted some business segments and some end markets.

REBITDA amounted to EUR 1,642 million down by (4)% versus the very demanding comparable of last year in the Plastics and Rhodia sectors. In Plastics, REBITDA declined by (14)% due to the demand decrease and margin squeeze in Vinyls while in Specialty Polymers volumes were up by +1%. REBITDA of the Chemicals sector came in at EUR 439 million, a 13% improvement yoy, which was supported by the sustained performance of Essential Chemicals. The (2)% lower REBITDA of the Rhodia sector reflected the margin squeeze in Polyamide Materials and the comparison to the Rare Earth exceptional pricing situation of last year, which were not fully compensated for by the strong growth in Consumer Chemicals and in Acetow & Eco Services. Group REBITDA margin on net sales amounted to 16.6% compared with 17.6% in the first nine months 2011.

REBITDA amounted to EUR (38) million for **New Business Development** and to EUR (78) million for **Corporate and Business Support** and included for both segments one-time items of EUR (11) million booked in the third quarter 2012.

Adjusted¹ EBIT amounted to EUR 1,079 million which is (13)% down versus the first nine months of 2011 mainly due to lower adjusted EBIT in Plastics and Rhodia (link to developments at cycle-sensitive businesses) and non-recurring charges linked to the integration and cost savings programs. On an IFRS basis EBIT amounted to EUR 935 million.

¹: Adjusted performance indicators exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.

SOLVAY ACCELERATES ITS DEVELOPMENT IN INDIA



Solvay has signed an agreement to acquire a controlling interest in Sunshield Chemicals, an Indian company specializing in surfactants. This acquisition will enable Novecare to accelerate growth plans in India for the h&p care, agrochemicals, coatings and industrial applications markets.

Solvay has also announced a capacity increase of 70% at its Panoli plant, for the production of its high performance polymers PEEK and PAEK. Nearly half of this capacity increase has already been implemented and successfully brought on-line. The second phase of the project will be completed by mid 2013 and will allow the plant to continue to satisfy growth in demand.

These developments follow the opening of a major innovation center in Savli (Gujarat State) and further reinforce the Group's presence and commitment in India. Moreover, Solvay is determined to double its sales in India by 2015.

PLASTICS

3RD QUARTER 2012 BUSINESS REVIEW*

Highlights

Specialty Polymers

- Sustained strong business momentum with Net Sales and REBITDA reaching new record levels of EUR 359 million and EUR 115 million respectively. Volumes up by 9% and REBITDA margin of 32%
- Operational excellence programs contributing to the results growth

Vinyls

- Continued challenging market conditions adversely impacting both volumes and prices
- Differentiated business dynamics by region

Key data (in million EUR)	Adjusted Q3 2012	YoY evolution (%)	Adjusted 9M 2012	YoY evolution (%)
Net sales	994	8%	2,943	3%
Specialty Polymers	359	18%	1,033	9%
Vinyls	635	3%	1,909	0%
Vinyls Europe	361	3%	1,096	(2)%
Vinyls Asia	99	6%	280	11%
Vinyls South America	142	5%	415	(1)%
Plastics Integration	34	(9)%	118	(11)%
REBITDA	168	8%	450	(14)%
Specialty Polymers	115	24%	313	8%
Vinyls	52	(13)%	138	(39)%
EBIT	102	0%	350	(2)%

Key data (in million EUR)	Q3 2012	YoY evolution (%)	9M 2012	YoY evolution (%)
EBIT IFRS	102	0%	350	(2)%

Net sales
EUR **994** million
+8%

REBITDA
EUR **168** million
+8%


YoY evolution (%) compared with pro forma 3rd quarter 2011

Specialty Polymers

Net sales of Specialty Polymers increased by 18% yoy and reached a new record of EUR 359 million in Q3'12. Prices increased by 1% and volumes rose by an impressive 9% compared to the same period last year. The 3rd quarter of 2012 benefited also from positive foreign exchange impacts of 7%. During the quarter, the most dynamic end markets were Smart Devices, Oil & Gas and Consumer applications. The Advanced Transportation, Healthcare and Water sectors remained highly resilient. Demand from the Construction and the Automotive industry was lackluster. Numerous operational excellence programs implemented over the year contributed to the results growth. The innovation development pool remains healthy with significant new promising projects to be launched in the following months.

REBITDA amounted to EUR 115 million up by 24% compared to the 3rd quarter of 2011. The REBITDA margin on net sales came in at 32%, versus the high level of 31% reached in Q3'11. The profitability of the activities was driven by volume growth, favorable product mix and pricing power through strong alignment with customers' needs.

3Q'12 net sales % YoY evolution




Vinyls

Net sales of Vinyls amounted to EUR 635 million, up by 3% compared to the still high level of 3rd quarter 2011. Volumes of PVC and caustic soda rose by 2% while volumes from other co-products went down leading to an overall volume reduction of (2)% yoy. In Europe, demand for PVC remained low and volatile as a consequence of important ethylene price movements. In Latin America, production was impacted by reduced ethylene supplies in Argentina but improved slightly in Brazil. In Thailand, Vinythai operated at full capacity.

REBITDA amounted to EUR 52 million, a decrease of (13)% yoy. In Europe, SolVin's spreads decreased yoy and qoq. Solvay Indupa's results suffered from lower spreads in Brazil. Vinythai continued to deliver strong results.

3Q'12 net sales % YoY evolution



Solvay's new SOLEF® production capacity strengthens its leadership in the growing specialty polymers market

Solvay announced the start up of new production capacity at its Tavaux plant, France, for SOLEF® Polyvinylidene fluoride (PVDF). Investment of EUR 26 million increased the PVDF production capacity at the plant by 50%. The outstanding properties of SOLEF® PVDF combined with the multiple available processing techniques make this fluorinated polymer a prime material for new applications in various demanding environments and applications.

CHEMICALS

3RD QUARTER 2012 BUSINESS REVIEW*

Highlights

- Essential Chemicals
 - REBITDA at EUR 132 million improved by 28% yoy based on pricing power and volume growth
 - REBITDA margin of 22%
- Special Chemicals
 - Volume flat but pricing in the refrigerants market less favorable compared to a strong 3rd quarter 2011

Key data (in million EUR)	Adjusted Q3 2012	YoY evolution (%)	Adjusted 9M 2012	YoY evolution (%)
Net sales	758	7%	2,253	5%
Essential Chemicals	598	8%	1,774	6%
EMEA ¹	366	3%	1,107	2%
North America	134	9%	390	10%
South America	38	39%	112	17%
Asia Pacific	60	26%	165	12%
Special Chemicals	159	5%	479	4%
REBITDA	145	21%	439	13%
Essential Chemicals	132	28%	394	24%
Special Chemicals	13	(13)%	45	(30)%
EBIT	99	30%	307	7%

Key data (in million EUR)	Q3 2012	YoY evolution (%)	9M 2012	YoY evolution (%)
EBIT IFRS	99	30%	307	7%

¹. Europe, Middle-East and Africa

Net sales
EUR **758** million
+7%

REBITDA
EUR **145** million
+21%

YoY evolution (%) compared with pro forma 3RD quarter 2011

Essential Chemicals

Net sales of Essential Chemicals amounted to EUR 598 million, up by 8% yoy, due to volume growth of 3% (growth in Latin America and Asia more than compensated slightly lower volumes in Europe), forex and pricing.

- **Soda ash** demand remained satisfactory. The lower demand for flat glass in Europe was compensated by good production and sales from the US. Demand in China stagnated. Bicarbonate volumes continued their volume growth. Net sales of soda ash and bicarbonate benefited from yoy price increases.

- In **hydrogen peroxide** demand remained strong. Selling prices rose yoy globally. Volumes decreased slightly versus the 3rd quarter 2011. This decrease is mainly to be ascribed to lower demand from pulp and paper in Europe. The other end markets such as chemicals, mining, alumina treatment and environmental applications continued to perform well.

- **Caustic soda** continued benefiting from good volumes, coupled with slightly higher selling prices yoy.

- Volumes in **epichlorohydrin** increased thanks to the new Epicerol® plant in Thailand but profitability was impacted by further declining selling prices and weak demand in epoxy resins.


REBITDA amounted to EUR 132 million, up by 28% versus the 3rd quarter of 2011. Overall higher volumes, increased selling prices and strong operational performance accounted for the improved results.

Special Chemicals


Net sales amounted to EUR 159 million, up by 5% compared to the 3rd quarter of 2011.

REBITDA amounted to EUR 13 million, compared to EUR 20 million in the 2nd quarter of 2012 and EUR 15 million YoY. Demand remained good in end-markets like agro, healthcare, electronics while results continued to be negatively impacted by pricing pressure in refrigerants and weak Life Science performance.

Special Chemicals - 3Q'12 net sales % YoY evolution



Essential Chemicals - 3Q'12 net sales % YoY evolution



JOINT VENTURE FOR F2 CLEANING GAS INCORPORATED

Solvay and Air Liquide have incorporated their worldwide fluorine gas business joint venture following the antitrust approvals.

This company will build, own and operate modular on-site fluorine cleaning gas units for the flat panel display and silicon thin film photovoltaic industries and thus offer these industries an economic, reliable and environmentally-friendly product for cleaning applications. Fluorine gas (F2) is a cleaning gas that has no global warming potential. It also enables our customers to increase their productivity.

RHODIA

3RD QUARTER 2012 BUSINESS REVIEW*

Highlights

- Profit growth continued to be driven by Consumer Chemicals and Acetow & Eco Services
- At Consumer Chemicals, Novecare still benefited from exceptional pricing opportunities at its Indian guar JV in a context of high demand before the new crop harvesting season
- Positive pricing power for the Sector with excellent performance across businesses except for Polyamide Materials and for Rare Earth's peak comparison (Advanced Materials)

Key data (in million EUR)	Adjusted Q3 2012	YoY evolution (%)	Adjusted 9M 2012	YoY evolution (%)
Net sales	1,540	(6)%	4,665	(1)%
Consumer Chemicals	677	16%	1,906	9%
Advanced Materials	181	(33)%	645	(4)%
Polyamide Materials	416	(13)%	1,314	(6)%
Acetow & Eco Services	237	8%	692	8%
Energy Services	30	(40)%	110	(27)%
REBITDA	290	4%	869	(2)%
Consumer Chemicals	162	105%	424	58%
Advanced Materials	41	(53)%	137	(35)%
Polyamide Materials	16	(69)%	97	(47)%
Acetow & Eco Services	64	28%	191	29%
Energy Services	26	(28)%	83	(31)%
Corporate & Others	(19)	21%	(63)	(47)%
EBIT	210	12%	569	(16)%

Key data (in million EUR)	Q3 2012	YoY evolution (%)	9M 2012	YoY evolution (%)
EBIT IFRS	179		424	

Net sales
 EUR **1,540** million
(6)%

REBITDA
 EUR **290** million
+4%


YoY evolution (%) compared with pro forma 3rd quarter 2011

Consumer Chemicals

Consumer Chemicals reported **net sales** of EUR 677 million, up by 16% versus last year. Novecare continued its strong performance. Its differentiating integrated position in guar allowed to enhance its commercial offering in guar derivatives. Further, native guar prices stood exceptionally high during the period but are currently reaching more normalized levels with the new crop season. Coatis posted lower net sales due to poor phenol volumes and prices. Aroma Performance improved sales and volumes on the back of both market share gains after its successful repositioning in food and strong dynamics in Agro and Pharma.

REBITDA more than doubled versus last year, reaching EUR 162 million. This was mainly driven by Novecare's enhanced guar-derivative formulation business, coupled with the exceptional pricing conditions enjoyed by its Indian native-guar JV that led to an improvement of about EUR 40 million versus last year. Coatis realized a slightly lower REBITDA yoy while Aroma delivered a stronger performance thanks to good volume growth. Overall, Consumer Chemicals posted increased volumes, favorable mix and excellent pricing power, resulting in a REBITDA margin at a high level of 24% compared to 14% last year.

3Q'12 net sales % YoY evolution




Advanced Materials

Net sales amounted to EUR 181 million, down by (33)% yoy, due to volumes and more normalized selling prices in rare earths. Overall volume decreased by (33)% due notably to Lighting customers' destocking in Rare Earths and to demand slowdown for Silica in Europe and to a lesser extent in Asia. The latter reflected lower activity levels in the tire replacement market and at Original Equipment Manufacturers. Higher Silica demand in the USA partly compensated for the weakness in other regions. Mixed Oxides demand for car catalysis applications within Rare Earths Systems remained stable.

REBITDA amounted to EUR 41 million, down by (53) % compared to the 3rd quarter 2011. Pricing power remained positive in Silica. Advanced Materials' REBITDA margin reached a good 23%, which as anticipated, stood lower than the 32% margin achieved in the year ago period with peak prices for rare earths. The Rare Earth Systems business started the full process to recycle heavy rare earths from phosphors in used fluorescent lamps in France.

3Q'12 net sales % YoY evolution



MULTI YEAR CONTRACT WITH BOLLORÉ GROUP

Aroma Performance will supply two Bolloré Group affiliates, Batscap and BatHium Canada Inc, with specialty Lithium Salt grades (LiTFSI) for their Lithium-Metal-Polymer® (LMP) batteries.


LiTFSI is the preferred option for Lithium-Metal-Polymer® (LMP) batteries developed by BatHium and BatScap. Its chemical and thermal stability combined with excellent electrochemical properties ensure a reinforced intrinsic safety and longer durability for fully electric vehicles such as the Bluecar®, the small fully electric powered city car from Autolib', that was created by the Bolloré Group.

Polyamide Materials

Net sales of EUR 416 million were down by (13)% yoy and (6)% qoq. Overall volumes dropped by (10)% reflecting lower dynamics across end-markets. The car industry though showed more resilience within the Engineering Plastics business unit. Market conditions continued deteriorating, eroding margins hit by very weak demand and industry overcapacity. The situation was most challenging for Polyamides & Intermediates while Fibras managed some net sales recovery versus the low levels of 3rd quarter 2011.

REBITDA dropped to EUR 16 million compared to EUR 52 million last year. Lackluster demand, deteriorating operating leverage, and poor pricing power were the factors behind the unsatisfactory performance.

3Q'12 net sales % YoY evolution




Acetow & Eco Services

Acetow & Eco Services realized **net sales** of EUR 237 million, up by 8% compared to the 3rd quarter of 2011. While overall volume declined by (5)%, the mix improved (less low value co-products) with volumes of filter tow rising. Selling prices were 4% higher and foreign exchange favorable of 9%. Eco Services reported activity levels corresponding to the usual high seasonality, but its volumes were somehow impacted by the Isaac hurricane.

REBITDA amounted to EUR 64 million, up by 28% compared to last year driven by strong pricing power and more favorable mix in both segments. Within the cluster, Acetow benefited from good take-off of innovative products with higher value added.

3Q'12 net sales % YoY evolution




Energy Services

REBITDA of Energy Services came in at EUR 26 million compared to EUR 36 million in the 3rd quarter 2011 mainly due to the poor liquidity of the carbon credit market during the 3rd quarter 2012. The level of CER volumes sold in the quarter halved yoy. Average CER price realized over the quarter was high at EUR 11.9 per ton versus EUR 11.0 in the 3rd quarter 2011.

Carbon credits production levels of 2012 are expected to remain stable at 14 million tons.

3Q'12 net sales % YoY evolution



CONSOLIDATED FINANCIAL STATEMENTS

INCOME STATEMENT 3RD QUARTER

	IFRS		Adjusted ¹	Pro forma ²
	2012	2011	2012	2011
Sales	3,371	1,632	3,371	3,354
Other non-core revenues	79	6	79	98
Net sales	3,291	1,626	3,291	3,256
Cost of goods sold	(2,731)	(1,322)	(2,731)	(2,662)
Gross margin	640	310	640	692
Commercial and administrative costs	(278)	(125)	(278)	(281)
Research and development costs	(65)	(31)	(65)	(54)
Other operating gains and losses	(16)	10	15	(12)
Earnings from associates and joint ventures accounted for using the equity method	71	14	71	21
REBITDA	554	264	554	533
REBIT	352	178	383	366
Non-recurring items	(54)	(30)	(54)	(11)
EBIT	298	148	329	355
Cost of borrowings	(53)	(36)	(53)	(53)
Interest on lendings and short-term deposits	3	11	3	4
Other gains and losses on net indebtedness	2	(5)	2	(15)
Cost of discounting provisions	(50)	(13)	(50)	(35)
Income/loss from available-for-sale investments	0	0	0	0
Result before taxes	200	104	231	256
Income taxes	(58)	(25)	(66)	(103)
Result from continuing operations	143	80	165	153
Result from discontinued operations	(2)	6	(2)	6
Net income	141	86	163	160
Non-controlling interests	(15)	(13)	(15)	(17)
Net income Solvay share	125	73	148	143
Basic earnings per share from continuing operations	1.54	0.81	1.82	1.68
Basic earnings per share from discontinued operations	(0.02)	0.08	(0.02)	0.07
Basic earnings per share	1.52	0.89	1.79	1.76
Diluted earnings per share from continuing operations	1.54	0.81	1.81	1.67
Diluted earnings per share from discontinued operations	(0.02)	0.08	(0.02)	0.07
Diluted earnings per share	1.51	0.89	1.79	1.75

1. Adjusted figures exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.

2. The 3rd quarter 2011 figures were restated to show the income statement (a) as if the acquisition of Rhodia had become effective from 1st of January 2011, (b) harmonizing the accounting principles and (c) eliminating the Purchase Price Allocation (PPA) impacts.

CONSOLIDATED FINANCIAL STATEMENTS

INCOME STATEMENT 9 MONTHS

	IFRS		Adjusted ¹	Pro forma ²
	2012	2011	2012	2011
Sales	10,126	5,020	10,126	9,991
Other non-core revenues	265	17	265	295
Net sales	9,861	5,003	9,861	9,696
Cost of goods sold	(8,106)	(3,996)	(8,106)	(7,790)
Gross margin	2,021	1,023	2,021	2,201
Commercial and administrative costs	(847)	(370)	(847)	(838)
Research and development costs	(196)	(94)	(196)	(156)
Other operating gains and losses	(108)	(1)	(9)	(34)
Earnings from associates and joint ventures accounted for using the equity method	159	36	159	53
REBITDA	1,642	853	1,642	1,711
REBIT	1,027	594	1,127	1,225
Non-recurring items	(93)	(30)	(48)	14
EBIT	935	563	1,079	1,239
Cost of borrowings	(154)	(108)	(154)	(159)
Interest on lendings and short-term deposits	13	31	13	21
Other gains and losses on net indebtedness	(3)	(10)	(3)	(28)
Cost of discounting provisions	(143)	(37)	(143)	(98)
Income/loss from available-for-sale investments	(1)	1	(1)	1
Result before taxes	646	441	790	976
Income taxes	(206)	(87)	(245)	(272)
Result from continuing operations	440	354	545	704
Result from discontinued operations	1	(38)	1	(38)
Net income	441	316	546	667
Non-controlling interests	(38)	(46)	(38)	(54)
Net income Solvay share	403	270	508	613
Basic earnings per share from continuing operations	4.89	3.79	6.17	8.01
Basic earnings per share from discontinued operations	0.01	(0.46)	0.01	(0.47)
Basic earnings per share	4.90	3.33	6.18	7.55
Diluted earnings per share from continuing operations	4.87	3.77	6.14	7.97
Diluted earnings per share from discontinued operations	0.01	(0.46)	0.01	(0.47)
Diluted earnings per share	4.88	3.31	6.15	7.51

1. Adjusted figures exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.

2. The 9 months 2011 figures were restated to show the income statement (a) as if the acquisition of Rhodia had become effective from 1st of January 2011, (b) harmonizing the accounting principles and (c) eliminating the Purchase Price Allocation (PPA) impacts.

Reconciliation between IFRS and Adjusted data

The table hereafter reconciles IFRS results (which include PPA impacts related to the Rhodia acquisition) with Adjusted results (which exclude non cash PPA impacts) for the 3rd quarter and the nine months period of 2012.

	IFRS Q3 2012	PPA impacts ¹	Adjusted Q3 2012	IFRS 9M 2012	PPA impacts ¹	Adjusted 9M 2012
Net Sales	3,291		3,291	9,861		9,861
REBITDA	554		554	1,642		1,642
REBIT	352	(31)	383	1,027	(99)	1,127
Non-recurring items	(54)		(54)	(93)	(45)	(48)
EBIT	298	(31)	329	935	(144)	1,079
Net financial expenses	(98)		(98)	(288)		(288)
Result before taxes	200	(31)	231	646	(144)	790
Income taxes	(58)	8	(66)	(206)	40	(245)
Net result from continuing operations	143	(23)	165	440	(105)	545
Net result from discontinued operations	(2)		(2)	1		1
Net income	141	(23)	163	441	(105)	546
Non controlling interests	(15)		(15)	(38)		(38)
Basic earnings per share	1.52		1.79	4.90		6.18
Net income, Group share	125	(23)	148	403	(105)	508

¹PPA impacts included (a) additional depreciation on fixed assets of EUR (99) million in the first nine months, EUR (31) million in the 3rd quarter 2012; (b) residual depreciation in Q1'12 of Rhodia inventory step up of EUR (45) million; and (c) EUR 40 million of associated tax impacts on the aforementioned items in the first nine months, EUR 8 million in the 3rd quarter 2012

Additional comments on the income statement of the 3rd quarter 2012 (IFRS/Adjusted)

Non-recurring items amounted to EUR (54) million. They primarily comprised EUR (36) million charges related to restructuring actions in the framework of the ongoing integration and cost savings programs, and EUR (12) million additional Health, Safety and Environment (HSE) provisions.

Net financial expenses amounted to EUR (98) million on an Adjusted and an IFRS basis. The cost of borrowings amounted to EUR (53) million. Gross financial debt (EUR 3,999 million) is for 78% covered at a fixed average rate of 5.6% with a duration of 4.23 years. Interest on cash deposits and investments amounted to EUR 3 million.

The cost of discounting provisions rose to EUR (50) million versus pro forma EUR (35) million last year. It includes the one-time effect of EUR (14) million caused by a reduction in discount rates for some HSE reserves versus the rates prevailing in Q2 '12.

Income taxes amounted to EUR (58) million in the IFRS accounts. On an Adjusted basis, income taxes totaled EUR (66) million representing a 28.6% effective tax rate. The EUR (8) million difference between IFRS and Adjusted figures reflects the tax impact of PPA adjustments.

Adjusted Net Income amounted to EUR 163 million compared to EUR 160 million pro forma last year. On an IFRS basis, Net Income amounted to EUR 141 million, the difference is explained by the after-tax global PPA impact. Results from discontinued operations in the quarter and year-to-date 2012 and 2011 recorded post-closure adjustments linked to the sale of the pharma operations.

Adjusted net Income, Group share amounted to EUR 148 million, resulting in EUR 1.79 Adjusted basic earnings per share. On an IFRS basis, net income, Group share amounted to EUR 125 million, the difference is explained by the after-tax global PPA impact.

STATEMENT OF COMPREHENSIVE INCOME (IFRS)

Million EUR	3 rd quarter		9 Months	
	2012	2011	2012	2011
Net income	141	86	441	316
Gains and losses on available-for-sale financial assets	4	(9)	13	(6)
Gains and losses on hedging instruments in a cash flow hedge	24	(3)	6	(4)
Actuarial gains and losses on defined benefit pension plans ¹	13	(12)	(234)	(35)
Currency translation differences	(105)	116	(78)	(81)
Share of other comprehensive income of associates and joint ventures accounted for using the equity method	11	(25)	25	(40)
Income tax relating to components of other comprehensive income	(4)	5	16	14
Other comprehensive income, net of related tax effects	(57)	73	(252)	(152)
Comprehensive income attributed to	83	159	190	164
Owners of the parent	76	143	158	141
Non-controlling interests	7	14	31	23

1. Increase in Net Pension Liabilities compared to the 2011 year-end situation primarily resulting from the reduction in discounting interest rates by 100 basis-points for EURO pension-related liabilities and 50 basis-points for GBP pension-related liabilities.

STATEMENT OF FINANCIAL POSITION (BALANCE SHEET)

Million EUR	September 30, 2012	December 31, 2011
Non-current assets	12,008	12,064
Intangible assets	1,504	1,705
Goodwill	2,716	2,599
Tangible assets	5,550	5,652
Available-for-sale investments	64	80
Investments in joint ventures and associates – equity method	850	704
Other investments	123	125
Deferred tax assets	793	780
Loans and other non-current assets	408	420
Current assets	6,835	7,373
Inventories	1,544	1,578
Trade receivables	1,921	2,311
Income tax receivables	51	43
Dividends receivable	0	0
Other current receivables - Financial instruments*	1,007	464
Other current receivables – Other	837	938
Cash and cash equivalents*	1,470	1,943
Assets held for sale	5	95
TOTAL ASSETS	18,844	19,437
Total equity	6,749	6,653
Share capital	1,271	1,271
Reserves	5,001	4,885
Non-controlling interests	477	497
Non-current liabilities	8,476	8,179
Long-term provisions: employees benefits	2,790	2,595
Other long-term provisions	1,293	1,325
Deferred tax liabilities	710	710
Long-term financial debt*	3,485	3,374
Other non-current liabilities	198	174
Current liabilities	3,620	4,605
Short-term provisions: employees benefits	62	39
Other short-term provisions	265	230
Short-term financial debt*	522	794
Trade liabilities	1,693	2,232
Income tax payable	140	51
Dividends payable	5	100
Other current liabilities	932	1,159
TOTAL EQUITY & LIABILITIES	18,844	19,437

*Net debt is the sum of Other current receivables- Financial Instruments Cash and cash equivalents, Long-term financial debt and Short-term financial debt

STATEMENT OF CHANGES IN EQUITY

Equity attributable to equity holders of the parent

						Fair value differences					
Million EUR	Share capital	Issue premiums	Retained earnings	Treasury shares	Currency translation diff.	Available for sale investments	Cash flow hedges	Defined benefit pension plans	Total	Non-controlling interests	Total equity
Balance – 31/12/2010	1,271	18	5,791	(301)	(374)	11	4	(131)	6,289	419	6,708
Net profit for the period			247						247	50	296
Income and expenses directly allocated to equity					42	(8)	8	(86)	(44)	(10)	(54)
Comprehensive income	0	0	247	0	42	(8)	8	(86)	202	40	242
Cost of stock options			9						9		9
Dividends			(250)						(250)	(14)	(263)
Acquisition/sale of treasury shares				10					10		10
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control			(100)						(100)	52	(48)
Other			(4)						(4)	0	(4)
Balance – 31/12/2011	1,271	18	5,693	(292)	(332)	3	12	(217)	6,156	497	6,653
Net profit for the period			403						403	38	441
Income and expenses directly allocated to equity					(47)	13	4	(214)	(244)	(7)	(252)
Comprehensive income	0	0	403	0	(47)	13	4	(214)	158	31	190
Cost of stock options			8						8		8
Dividends			(153)						(153)	(23)	(177)
Acquisition/sale of treasury shares				111					111		111
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control			(3)						(3)	(30)	(33)
Other			(6)						(6)	3	(3)
Balance – 30/09/2012	1,271	18	5,942	(180)	(379)	16	16	(431)	6,271	477	6,749

CASH FLOW STATEMENT (IFRS)

Million EUR	3 rd quarter		9 months	
	2012	2011	2012	2011
EBIT	295	152	932	520
Depreciation, amortization and impairments	201	87	616	263
Changes in working capital	154	91	(167)	(203)
Changes in provisions	(6)	(83)	(65)	(131)
Dividends received from associates and joint ventures accounted for using the equity method	24	7	48	37
Income taxes paid	(44)	(32)	(109)	(89)
Others ¹	(110)	(23)	(305)	(65)
Cash flow from operating activities	514	199	949	332
Acquisition (-) of subsidiaries	0	(3,953)	0	(3,953)
Acquisition (+) of Rhodia's cash	0	931	0	931
Acquisition (-) of investments - Other	(13)	(53)	(24)	(183)
Sale (+) of subsidiaries	0	0	0	0
Sale (+) of investments - Others	5	1	178	1
Acquisition (-) of tangible and intangible assets	(176)	(111)	(500)	(252)
Sale (+) of tangible and intangible assets	10	0	75	5
Income from available-for-sale investments	0	0	1	1
Changes in non-current financial assets	(2)	28	11	57
Cash flow from investing activities	(176)	(3,157)	(259)	(3,393)
Capital increase (+) / redemption (-)	0	52	(29)	32
Acquisition (-) / sale (+) of treasury shares	5	(16)	111	13
Changes in borrowings	(100)	74	(390)	124
Changes in other current financial assets	(225)	981	(376)	3,546
Cost of borrowings	(53)	(37)	(154)	(108)
Interest on lendings and short-term deposits	3	11	13	31
Other	2	(5)	(58)	(10)
Dividends paid	(11)	3	(272)	(264)
Cash flow from financing activities	(379)	1,063	(1,155)	3,364
Net change in cash and cash equivalents	(41)	(1,895)	(464)	302
Currency translation differences	(14)	6	(11)	(6)
Others	0	0	2	0
Opening cash balance	1,525	4,139	1,943	1,954
Closing cash balance	1,470	2,250	1,470	2,250
Free Cash Flow² from continuing operations	351	118	450	161
Free Cash Flow² from discontinued operations	(5)	(2)	86	(18)
Total Free Cash Flow²	346	116	536	143

1. During Q3'12, other operating cash flows included non-cash earnings from equity associates EUR (71) million, non cash discounting costs EUR (50) million reflected in change in provisions, and other minor non cash elements EUR 9 million. For the first 9 months, other operating cash flows included non-cash earnings from equity associates EUR (159) million, non cash discounting costs EUR (140) million reflected in change in provisions, reclassification of capital gain EUR (116) million into investing cash flow, PPA impacts on revaluation of Rhodia inventories EUR 45 million, non recurring provisions EUR 34 million and other minor non cash elements EUR 31 million

2. Cash flow from operating activities (including dividends from associates and joint ventures) + cash flow from investing activities (excluding acquisitions and sales of subsidiaries and other investments).

CASH FLOW FROM DISCONTINUED OPERATIONS

Million EUR	3 rd quarter		9 months	
	2012	2011	2012	2011
Cash flow from operating activities	(5)	(2)	133	(18)
Cash flow from investing activities	0	0	0	0
Cash flow from financing activities	0	0	(47)	0
Net change in cash and cash equivalents	(5)	(2)	86	(18)

Additional comments on the cash flow statement of the 3rd quarter 2012

Cash flow from operating activities was EUR 514 million compared to EUR 199 million last year. Besides an EBIT of EUR 295 million it consisted of

- Depreciation, amortization and impairments amounted to EUR 201 million
- Working capital decreased by EUR 154 million

Cash flow from investing activities as well as capital expenditures amounted to EUR (176) million.

Free Cash Flow was EUR 346 million, and included cash flow from discontinued operations for EUR (5) million linked to post-closing adjustments subsequent to the sale of the pharmaceutical activities.

RESULTS BY SEGMENT BEFORE ELIMINATION OF INTER-COMPANY SALES

Million EUR	3 rd quarter		9 months	
	2012	2011	2012	2011
Net sales	3,291	1,626	9,861	5,003
Plastics				
Net sales	1,056	974	3,143	3,070
Inter-segments sales	(62)	(54)	(200)	(206)
External sales	994	920	2,943	2,864
Chemicals				
Net sales	800	734	2,351	2,217
Inter-segments sales	(42)	(28)	(98)	(77)
External sales	758	706	2,253	2,139
Rhodia				
Net sales	1,543		4,672	
Inter-segments sales	(3)		(6)	
External sales	1,540		4,665	
REBITDA	554	264	1,642	853
Plastics	168	154	450	520
Chemicals	145	117	439	382
Rhodia	290		869	
New Business Development	(17)	(8)	(38)	(22)
Corporate and business support	(32)	1	(78)	(27)
REBIT	352	178	1,027	594
Plastics	117	107	304	377
Chemicals	105	79	319	272
Rhodia	182		527	
New Business Development	(17)	(8)	(39)	(22)
Corporate and business support	(34)	(1)	(83)	(32)
EBIT	298	148	935	563
Plastics	102	102	350	359
Chemicals	99	76	307	286
Rhodia	179		424	
New Business Development	(17)	(8)	(39)	(22)
Corporate and business support	(65)	(23)	(107)	(60)

NOTES TO THE ACCOUNTS

1. Consolidated financial statements

The consolidated financial statements were prepared in conformity with IFRS standards as currently adopted in the European Union. The same accounting policies have been implemented as for the latest annual financial statements. The primary variations in scope between the first nine months of 2011 and 2012 were due to:

- Treatment of the PipeLife stake in Solvay's accounts until its effective disposal in May 2012: PipeLife stake has been accounted for as an "investment held for sale" as of December 31st, 2011, following the decision to sell the 50% stake in PipeLife to Wienerberger in February 2012.

2. Content

This results report contains regulated information and is established in compliance with IAS 34. A risk analysis is included in the annual report, which is available on www.solvay.com.

3. Primary exchange rates

1 Euro		Closing			Average		
		9 months 2012	9 months 2011	2011	9 months 2012	9 months 2011	2011
Pound Sterling	GBP	0.798	0.867	0.835	0.812	0.871	0.868
American Dollar	USD	1.293	1.350	1.294	1.281	1.407	1.392
Argentine Peso	ARS	6.068	5.678	5.577	5.724	5.757	5.754
Brazilian Real	BRL	2.623	2.507	2.416	2.456	2.294	2.327
Thai Baht	THB	39.811	42.048	40.991	39.977	42.641	42.430
Japanese Yen	JPY	100.370	103.790	100.200	101.615	113.190	110.960

4. Solvay shares

	Q3 2012	YTD 2012	Q3 2011	YTD 2011
Number of shares issued at the end of the period	84,701,133	84,701,133	84,701,133	84,701,133
Average number of shares for IFRS calculation of earnings per share	82,515,160	82,168,943	81,410,587	81,237,210
Average number of shares for IFRS calculation of diluted income per share	82,884,711	82,508,827	81,816,704	81,633,531

5. Purchase Price Allocation related to the acquisition of Rhodia

Solvay acquired 95.9% shares and voting rights of Rhodia and 97.51% "OCEANE" convertible bonds on September 7, 2011. Solvay implemented the squeeze-out for the remaining shares (4.1%) and convertible bonds on September 15, 2011.

This transaction was accounted for in accordance with IFRS 3 – "Business Combinations". According to this standard, the acquirer has from the acquisition date a period of maximum one year to finalize the recognition and measurement at fair value of the assets acquired and liabilities assumed.

During the measurement period, the acquirer shall retrospectively adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about the facts and circumstances that existed as at the acquisition date.

Thus, the provisional accounting recognized for the acquisition of Rhodia as presented in the 2011 annual financial statements were completed during the 3rd quarter of 2012. The adjustments retrospectively recorded at the acquisition date are detailed in the table below.

Million EUR	Provisional allocation (as published in FY 2011)	Adjustments	Final purchase price allocation	Acquisition of 95,9% of total shares	4,1% remaining shares squeeze out
Fixed assets	2,164	(12)	2,152	2,064	
Intangible assets	1,607	(84)	1,523	1,460	
Joint ventures - equity method	104	(2)	102	97	
Other long term assets	120		120	115	
Working capital	752	(8)	744	714	
Assets held for sale	34		34	33	
Provisions	(2,045)	(41)	(2,086)	(2,000)	
Contingent liabilities	(100)	14	(86)	(83)	
Deferred taxes	(504)	14	(490)	(470)	
Current taxes	(15)	(1)	(16)	(16)	
Long term financial assets	(72)		(72)	(69)	
Financial Debt	(1,578)		(1,578)	(1,513)	
Cash and cash equivalents	931		931	893	
Net Assets	1,398	(120)	1,278	1,225	52
Purchase consideration	3,876		3,876	3,876	137
Goodwill				2,651	
Reduction in equity					85
Cash flow statement reconciliation					
Consideration paid for Rhodia acquisition, net of cash and cash equivalents acquired				2,923	

Description of adjustments and retrospective impacts

- The value of the technologies used in the activities of Polyamides and Intermediates, initially estimated at EUR 94 million, was after more detailed studies, not recognized in the final acquisition balance sheet. As a consequence, the depreciation charges recognized since 30 September 2011 were reversed (quarterly depreciation charge of EUR 2 million)
- Following a detailed review of the deferred taxes, no deferred tax asset was longer accounted for the activities of Rhodia Brazil (difference of EUR 38 million compared to the initial provisional booking)
- The fair value of the environmental provisions was reassessed for an additional amount of EUR 35 million

The goodwill primarily reflects the expected synergies in global procurement and logistics and in administrative and process efficiencies, as well as future developments of activities. Recurring yearly savings linked to synergies are estimated at EUR 255 million, a yearly run rate that is to be reached as at the start of 2015. Management's estimate of future synergies which are included in the goodwill are based on the expected cost reductions through integration of Solvay and Rhodia's best practices in terms of global procurement of raw materials and energy, logistics & packaging, general & IT expenses, technical goods and services.

The fair value of "loans and other non-current assets" and of "working capital" includes trade and other receivables for an amount of EUR 998 million. The gross contractual amount of these receivables is EUR 1,058 million, including EUR 60 million for which the collection is not expected.

In 2012, the goodwill allocation resulting from the acquisition of Rhodia (EUR 2,651 million) to CGUs (cash-generating units) and operating segments was completed as follows

Operating segments	Goodwill allocated
Chemicals segment	81
Plastics segment	345
Rhodia segment	456
Cash Generating Units	Goodwill allocated
Novecare	477
Polyamides	170
Rare Earths	161
Specialty Polymers	147
Acetow	120
Soda ash and derivatives Europe	120
Aromas	82
Vinyls Europe	77
Silica	72
Coatis	49
Energy Services	47
Special chemicals	42
Eco Services	42
Soda ash and derivatives Nafta	42
Chlorin Europe	42
Hydrogen Peroxide Europe	20
Vinyls Asia	18
Hydrogen Peroxide Mercosul	14
Olefins	11
Hydrogen Peroxide Nafta	7
Hydrogen Peroxide Asia	5
Plastics integration	4
Total Goodwill	2,651

The impairment test of the corresponding CGUs is performed at year-end.

6. Declaration by responsible persons

Jean-Pierre Clamadieu, Chief Executive Officer, and Bernard de Laguiche, Chief Financial Officer, of the Solvay Group, declare that to the best of their knowledge:

- a. The summary financial information, prepared in conformity with applicable accounting standards, reflects a faithful image of the net worth, financial situation and results of the Solvay Group;
- b. The intermediate report contains a faithful presentation of significant events occurring during the nine first months of 2012, and their impact on the summary financial situation;
- c. There are no transactions with related parties;
- d. The main risks and uncertainties over the remaining months within the 2012 fiscal year stand in accordance with the assessment disclosed in the section “Risk Management” in the Solvay’s 2011 Annual Report taking into account the current economic and financial environment.

7. Limited review report

Solvay SA/NV

Limited review report on the consolidated interim financial information for the nine-months period ended 30 September 2012

To the board of directors

We have performed a limited review of the accompanying consolidated statement of financial position, the consolidated income statement, the consolidated statement of comprehensive income, the consolidated cash flow statement, the consolidated statement of changes in equity and selective notes (jointly the “interim financial information”) of Solvay SA/NV (“the company”) and its subsidiaries (jointly “the group”) for the nine-months period ended 30 September 2012. The board of directors of the company is responsible for the preparation and fair presentation of this interim financial information. Our responsibility is to express a conclusion on this interim financial information based on our review.

The interim financial information has been prepared in accordance with international financial reporting standard IAS 34 – Interim Financial Reporting as adopted by the European Union.

Our limited review of the interim financial information was conducted in accordance with international standard ISRE 2410 – Review of interim financial information performed by the independent auditor of the entity. A limited review consists of making inquiries of group management and applying analytical and other review procedures to the interim financial information and underlying financial data. A limited review is substantially less in scope than an audit performed in accordance with the International Standards on Auditing (ISA). Accordingly, we do not express an audit opinion on the interim financial information.

Based on our limited review, nothing has come to our attention that causes us to believe that the interim financial information for the nine-months period ended 30 September 2012 is not prepared, in all material respects, in accordance with IAS 34 – Interim Financial Reporting as adopted by the European Union.

Diegem, 24 October 2012

The statutory auditor

DELOITTE Bedrijfsrevisoren / Reviseurs d’Entreprises

BV o.v.v.e. CVBA / SC s.f.d. SCRL

Represented by Eric Nys

GLOSSARY

Adjusted performance indicators exclude Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition.

Adjusted basic earnings per share

Adjusted net income (Solvay share) divided by the weighted average number of shares, after deducting own shares purchased to cover stock option programs

Adjusted net income (Solvay share)

Net income (Solvay share) excluding Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition

Adjusted net result

Net result excluding Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition

Adjusted REBIT

REBIT excluding Purchase Price Allocation (PPA) non-cash accounting impacts related to the Rhodia acquisition

Basic earnings per share

Net income (Solvay's share) divided by the weighted average number of shares, after deducting own shares purchased to cover stock option programs

EBIT

Operating results

Free cash flow

Cash flow from operating activities (including dividends from associates and joint ventures)+ cash flow from investing activities (excluding acquisitions and sales of subsidiaries and other investments).

IFRS

International Financial Reporting Standards

Net financial expenses

Net financial expenses comprises cost of borrowings minus accrued interests on lendings and short-term deposits, plus other gains (losses) on net indebtedness and costs of discounting provisions (namely, related to Post-employment benefits and HSE liabilities)

Net sales

Sales of goods and value added services corresponding to Solvay's know-how and core business. Net sales exclude other revenues primarily comprising commodity and utility trading transactions and other revenue deemed as incidental by the Group

Pro forma figures

Figures that represent (a) as if the acquisition had become effective from 1st of January 2011, (b) harmonizing accounting principles and (c) eliminating the Purchase Price Allocation (PPA) impacts.

REBIT

Operating result, i.e. EBIT before non-recurring items

REBITDA

REBIT before depreciation and amortization

Key dates for investors

January 17, 2013: Payment of interim dividend for 2012

February 14, 2013: Announcement of the 4th quarter and full year 2012 results (at 07:30)

For additional information

> Lamia Narcisse

Media Relations

Tel: +33 (0)1 53 56 59 62

E-mail: lamia.narcisse@eu.rhodia.com

> Erik De Leye

Media Relations

Tel: +32 2 264 15 30

E-mail: erik.deleye@solvay.com

> Maria Alcon Hidalgo

Investor Relations

Tel: +32 2 264 19 84

E-mail: maria.alconhidalgo@solvay.com

> Patrick Verelst

Investor Relations

Tel: +32 2 264 15 40

E-mail: patrick.verelst@solvay.com

Solvay Investor Relations

E-mail: investor.relations@solvay.com

SOLVAY is an international chemical Group committed to sustainable development with a clear focus on innovation and operational excellence. It generates over 90% of its sales in markets where it is among the top three leaders. Solvay offers a broad range of products that contribute to improving the quality of life and the performance of its customers in markets such as consumer goods, construction, automotive, energy, water and environment, and electronics. The Group is headquartered in Brussels, employs about 31,000 people in 55 countries and generated EUR 12.7 billion in net sales in 2011. Solvay SA (SOLB.BE) is listed on NYSE Euronext in Brussels and Paris (Bloomberg: SOLB.BB - Reuters: SOLBt.BR).



a Passion for Progress®

Ce rapport est aussi disponible en français – Dit verslag is ook in het Nederlands beschikbaar